Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development
Open Access
- 1 March 2012
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 11 (3), 517-525
- https://doi.org/10.1158/1535-7163.mct-11-0454
Abstract
Mesothelin is a tumor differentiation antigen that is highly expressed in several malignant diseases in humans, including malignant mesothelioma and pancreatic, ovarian, and lung adenocarcinomas. The limited expression of mesothelin on normal human tissues and its high expression in many common cancers make it an attractive candidate for cancer therapy. Several agents, including an immunotoxin, monoclonal antibody, antibody drug conjugate, and tumor vaccine, are in various stages of development to treat patients with mesothelin-expressing tumors. This review highlights ongoing clinical trials, as well as other approaches to exploit mesothelin for cancer therapy, that are in preclinical development. Mol Cancer Ther; 11(3); 517–25. ©2012 AACR.Keywords
This publication has 49 references indexed in Scilit:
- Pentostatin Plus Cyclophosphamide Safely and Effectively Prevents Immunotoxin Immunogenicity in Murine HostsClinical Cancer Research, 2011
- Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing CancersClinical Cancer Research, 2010
- Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated TumorCancer Research, 2010
- Inhibition of mesothelin–CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapyLung Cancer, 2010
- The Human Cancer Antigen Mesothelin Is More Efficiently Presented to the Mouse Immune System when Targeted to the DEC‐205/CD205 Receptor on Dendritic CellsAnnals of the New York Academy of Sciences, 2009
- Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domainsProceedings of the National Academy of Sciences of the United States of America, 2009
- Mesothelin targeted cancer immunotherapyEuropean Journal Of Cancer, 2008
- Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumorsProceedings of the National Academy of Sciences of the United States of America, 2007
- Control of human mesothelin-expressing tumors by DNA vaccinesGene Therapy, 2007
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006